Author

M. Wieczorek

Observed name: Maciej Wieczorek

Institution: Celon Pharma (Poland)

Observed institution: Celon Pharma (Poland)

OpenAlex ID: A5083205655

46O Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies

2023 · I. Lugowska, A. Stanczak, et al. · ESMO Open · 1

Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy

2026 · Agata Mikołajczyk, Delfina Popiel, et al. · Frontiers in Pharmacology

Uncovering mechanistic differences among PDE10A inhibitors: a multilevel molecular, functional and behavioral comparison underlying the clinical efficacy of CPL’36

2026 · J. Krzemień, S. Kokhanovska, et al. · Neuroscience Applied

47P Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy

2024 · M.M. Skupinska, M. Walczak, et al. · ESMO Open

Design and development of an innovative, safe, and highly potent E1 ubiquitin-activating enzyme inhibitor CPL–410-005 conjugate in anticancer therapy

2022 · F. Mituła, M. Równicki, et al. · European Journal of Cancer

EP16.03-014 Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS

2022 · J. Moes-Sosnowska, M. Skupinska, et al. · Journal of Thoracic Oncology

Works count: 6

Citation count: 1

H-index: 1

I10-index: